Pathways to Personalization: Implementing Biologics in COPD Treatment
Released On
November 12, 2025
Expires On
November 12, 2026
Media Type
Internet
Completion Time
45 minutes
Specialty
Pulmonology
Topics
Respiratory
Providers/Grant Support
This activity is provided by Integrity CE, LLC.
DISCLOSURE OF COMMERCIAL SUPPORT
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Credit Available
- Physicians - maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity addresses the needs of physicians, physician assistants, nurse practitioners, respiratory therapists, and nurses involved in the management of patients with chronic obstructive pulmonary disease (COPD).
Program Overview
COPD is a highly heterogeneous condition that affects patients across a broad range of severities. Historically, clinicians have had limited treatment options for patients who remain symptomatic despite maximal inhaled or standard therapy. With growing insight into COPD’s molecular mechanisms, biologic therapies have emerged as a new frontier, leading to FDA approval of dupilumab in 2024 and mepolizumab in 2025, with additional agents in development. This program aims to test clinician knowledge regarding the evolution of biologic treatments and their role in shifting COPD care from a uniform to a precision-based approach. Clinicians will receive immediate feedback on their clinical decision-making in each case, with expert faculty providing guidance on optimal care.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Outline unmet needs in COPD patient management and the immuno-inflammatory rationale for biologics to address these needs
- Implement the use of available biologics in the treatment of patients with COPD based on GOLD guidelines and clinical evidence
- Describe emerging pathophysiologic treatment targets including mucus hypersecretion and their potential impact in COPD management
Faculty
Surya P. Bhatt, MD, MSPH
Professor of Medicine
Director, Center for Lung Analytics and Imaging Research (CLAIR)
University of Alabama at Birmingham
Birmingham, Alabama
Gerald J. Criner, MD
Professor and Founding Chair
Department of Thoracic Medicine and Surgery
Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania
Nicola A. Hanania, MD, MS
Professor of Medicine
Director of Airways Clinical Research Center
Baylor College of Medicine
Chief, PCCM, Ben Taub Hospital
Houston, Texas
Dave Singh MD, FERS, FBPhS
Professor of Clinical Pharmacology and Respiratory Medicine
University of Manchester
Medical Director, Medicines Evaluation Unit an IQVIA Business
Manchester, United Kingdom
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Surya P. Bhatt, MD, MSPH
Advisory Boards & Consulting: Apreo, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GSK, Merck, Polarean, Sanofi, Regeneron, Verona Pharma
Research Support (to institution): Genentech, Nuvaira Inc., Sanofi
Royalties: Springer
Gerald J. Criner, MD
Advisor: Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, EOLO Medical, Gala Therapeutics, GSK, Helios Medical, Ion, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, Pulmonx, Respironics Inc., Respivant Sciences, The Implementation Group, Verona Pharma
Research Support: ALung Technologies Inc., American College of Radiology, American Lung Association, AstraZeneca, BioScale Inc., Boehringer Ingelheim, BREATH Therapeutics Inc., COPD Foundation, Coridea/ZIDAN, Corvus, Dr. Karen Burns of St. Michael's Hospital, Fisher & Paykel Healthcare Ltd, Galapagos NV, GSK, Kinevent, Lungpacer Medical Inc., National Heart Lung & Blood Institute, Nurvaira Inc., Patient-Centered Outcomes Research Institute, Pulmonary Fibrosis Foundation, Pulmonx, Respironics Inc., Respivant Sciences, Spiration Inc. Steward St Elizabeth's Medical Center of Boston Inc., Veracyte Inc
Nicola A. Hanania, MD, MS
Consultant/Advisor: Amgen, AstraZeneca, Chiesi, Connect Biopharma, Genentech, GSK, Regeneron, Sanofi
Research Support (Institution): Amgen, AstraZeneca, Chiesi, Genentech, GSK, Regeneron, Sanofi
Dave Singh MD, FERS, FBPhS
Consultant: AstraZeneca, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GSK, Glenmark, Gossamer Bio, Kinaset Therapeutics, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Teva, Theravance Biopharma, Verona Pharma
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 12, 2025 through November 12, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 16% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].